Skip to main content
Sign In
 

Institutional Biosafety Committee

Office of Research Committee Support


E-mail: IBC@ucdenver.edu

The University Biosafety Committee provides review and approval of all recombinant DNA research, including Human Gene Transfer clinical trials, and review and approval of all Select Agents Research. Protocols are reviewed and overseen for compliance with the National Institute of Health (NIH) Guidelines and Federal Select Agents Regulations.

IBC Compliance Note: NIH Guidelines

The IBC meets monthly to review to and approve Biosafety Applications.


Responsibilities of the IBC

  • Review and approval of research involving recombinant DNA materials, including transgenic animals, plants and Human Subjects Gene Transfer clinical trials for regulatory compliance, safety, and containment of biological materials.
  • Review and approval of Biosafety Authorization Forms for work with infectious biological materials for regulatory compliance, safety, and containment of biological materials.
  • Review and approval of Biosafety Authorization Forms for all work with Select Agents Toxins for regulatory compliance, safety, and containment of SA materials.
  • Incident Reporting and Investigations for incidents involving infectious or recombinant DNA materials.

Biosafety Authorization F​orms

Any new or renewal IBC application submitted after 12:00pm on 2 April, 2018 must be entered in the eSirius system- word files will not be accepted for new/renewal applications after that time. For amendments, please contact the IBC office for amendment instructions or with any questions regarding the application process.


NIH References

​​​​​​​​​​